PMID- 38041150
OWN - NLM
STAT- MEDLINE
DCOM- 20231204
LR  - 20240112
IS  - 2050-6511 (Electronic)
IS  - 2050-6511 (Linking)
VI  - 24
IP  - 1
DP  - 2023 Dec 1
TI  - Efficacy and safety of thrombopoietin receptor agonists in solid tumors with 
      chemotherapy-induced thrombocytopenia: a meta-analysis.
PG  - 71
LID - 10.1186/s40360-023-00707-5 [doi]
LID - 71
AB  - OBJECTIVE: To evaluate the efficacy and safety of thrombopoietin receptor 
      agonists (TPO-RAs) in solid tumors with chemotherapy-induced thrombocytopenia 
      (CIT). METHODS: We conducted a comprehensive search of PubMed, FMRS, Cochrane 
      Library, Web of Science, EMBASE, and ClinicalTrials.gov for randomized controlled 
      trials (RCTs) reporting the efficacy and safety of TPO-RAs in solid tumors with 
      CIT. The search was limited to articles published before April 30, 2022. Primary 
      outcomes included chemotherapy dose reduction or delays, platelet transfusion, 
      the incidence of grade 3 or 4 thrombocytopenia, and bleeding events. Secondary 
      outcomes encompassed the incidence of platelet count > 400 x 10(9)/L, adverse 
      events (AEs), serious AEs, thrombosis, and mortality. RESULTS: Our analysis 
      encompassed six studies: five rigorous RCTs and one unique study comparing 
      romiplostim to an observation group, involving a total of 489 patients. For 
      primary outcomes, TPO-RAs significantly reduced the incidence of grade 3 or 4 
      thrombocytopenia (RR = 0.69, 95% CI: 0.52-0.91). After applying the Bonferroni 
      correction for multiple comparisons, the significance of the reduction in grade 3 
      or 4 thrombocytopenia incidence persisted (P = 0.008). TPO-RAs showed no 
      significant impact on chemotherapy dose reduction or delays (RR = 0.81, 95% CI: 
      0.65-1.01), platelet transfusion (RR = 1.04, 95% CI: 0.48-2.27), or bleeding 
      events (RR = 0.50, 95% CI: 0.23-1.10). In terms of safety, there were no 
      significant difference in the incidence of any AEs (RR = 0.98, 95% CI:0.92-1.04), 
      serious AEs (RR = 0.79, 95% CI:0.45-1.40), thrombotic events (RR = 1.20, 95% 
      CI:0.51-2.84) and mortality (RR = 1.15, 95% CI:0.55-2.41). CONCLUSIONS: This 
      meta-analysis suggests that TPO-RAs are generally well-tolerated. However, their 
      efficacy in solid tumors with CIT appears limited, as they only demonstrate a 
      reduction in the incidence of grade 3 or 4 thrombocytopenia.
CI  - (c) 2023. The Author(s).
FAU - Chen, Wen
AU  - Chen W
AD  - Department of Medical Oncology, Chongqing University Cancer Hospital, Chongqing, 
      400030, China.
FAU - Liu, Yubingxue
AU  - Liu Y
AD  - Department of Health Examination and Oncology Screening Center, Chongqing 
      University Cancer Hospital, Chongqing, 400030, China.
FAU - Li, Luchun
AU  - Li L
AD  - Department of Medical Oncology, Chongqing University Cancer Hospital, Chongqing, 
      400030, China.
FAU - Zeng, Xianghua
AU  - Zeng X
AD  - Department of Medical Oncology, Chongqing University Cancer Hospital, Chongqing, 
      400030, China. zengxh0803@163.com.
LA  - eng
GR  - No.cstc2018jcyjAX0814/Natural Science Foundation of Chongqing, China/
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20231201
PL  - England
TA  - BMC Pharmacol Toxicol
JT  - BMC pharmacology & toxicology
JID - 101590449
RN  - 0 (Receptors, Thrombopoietin)
RN  - 0 (Benzoates)
RN  - 0 (Hydrazines)
RN  - 0 (Pyrazoles)
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Humans
MH  - Receptors, Thrombopoietin/agonists/therapeutic use
MH  - Benzoates/adverse effects
MH  - Hydrazines/adverse effects
MH  - Pyrazoles/adverse effects
MH  - *Neoplasms/drug therapy
MH  - Hemorrhage/chemically induced
MH  - *Thrombocytopenia/chemically induced/drug therapy
MH  - *Antineoplastic Agents/adverse effects
PMC - PMC10693054
OTO - NOTNLM
OT  - Chemotherapy-induced thrombocytopenia
OT  - Meta-analysis
OT  - Randomized controlled trials
OT  - Solid tumors
OT  - Thrombopoietin receptor agonists
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest. The authors declare no competing interests.
EDAT- 2023/12/02 06:41
MHDA- 2023/12/04 12:42
PMCR- 2023/12/01
CRDT- 2023/12/02 00:02
PHST- 2023/05/24 00:00 [received]
PHST- 2023/11/14 00:00 [accepted]
PHST- 2023/12/04 12:42 [medline]
PHST- 2023/12/02 06:41 [pubmed]
PHST- 2023/12/02 00:02 [entrez]
PHST- 2023/12/01 00:00 [pmc-release]
AID - 10.1186/s40360-023-00707-5 [pii]
AID - 707 [pii]
AID - 10.1186/s40360-023-00707-5 [doi]
PST - epublish
SO  - BMC Pharmacol Toxicol. 2023 Dec 1;24(1):71. doi: 10.1186/s40360-023-00707-5.